EP2451816A4 - Forme cristalline d'hydrobromure de prasugrel et son procédé de préparation - Google Patents

Forme cristalline d'hydrobromure de prasugrel et son procédé de préparation

Info

Publication number
EP2451816A4
EP2451816A4 EP10796816A EP10796816A EP2451816A4 EP 2451816 A4 EP2451816 A4 EP 2451816A4 EP 10796816 A EP10796816 A EP 10796816A EP 10796816 A EP10796816 A EP 10796816A EP 2451816 A4 EP2451816 A4 EP 2451816A4
Authority
EP
European Patent Office
Prior art keywords
preparation
application
crystalline form
prasugrel hydrobromide
prasugrel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10796816A
Other languages
German (de)
English (en)
Other versions
EP2451816A1 (fr
Inventor
Srinivas Sanikommu Reddy
Shankar Sanganabhatla
Antyakula Pydi Bhaskar Rao
Mubeen Ahmed Khan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glenmark Generics Ltd
Original Assignee
Glenmark Generics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Generics Ltd filed Critical Glenmark Generics Ltd
Publication of EP2451816A1 publication Critical patent/EP2451816A1/fr
Publication of EP2451816A4 publication Critical patent/EP2451816A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP10796816A 2009-07-06 2010-06-25 Forme cristalline d'hydrobromure de prasugrel et son procédé de préparation Withdrawn EP2451816A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1596MU2009 2009-07-06
PCT/IN2010/000435 WO2011004392A1 (fr) 2009-07-06 2010-06-25 Forme cristalline d'hydrobromure de prasugrel et son procédé de préparation

Publications (2)

Publication Number Publication Date
EP2451816A1 EP2451816A1 (fr) 2012-05-16
EP2451816A4 true EP2451816A4 (fr) 2013-02-27

Family

ID=43428854

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10796816A Withdrawn EP2451816A4 (fr) 2009-07-06 2010-06-25 Forme cristalline d'hydrobromure de prasugrel et son procédé de préparation

Country Status (2)

Country Link
EP (1) EP2451816A4 (fr)
WO (1) WO2011004392A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2398468B1 (fr) 2009-02-17 2016-11-30 KRKA, D.D., Novo Mesto Compositions pharmaceutiques comprenant du prasugrel ou ses sels d'addition d'acide pharmaceutiquement acceptables, et leurs procédés de préparation
WO2010111951A1 (fr) * 2009-03-31 2010-10-07 上海医药工业研究院 Cristaux de bromhydrate de prasugrel
EP2360159A1 (fr) * 2010-02-11 2011-08-24 Ratiopharm GmbH Prasugrel de forme cristalline et micronisée et composition pharmaceutique le contenant
EP2883877A1 (fr) 2010-04-08 2015-06-17 Teva Pharmaceutical Industries, Ltd. Formes cristallines de sels de prasugrel
CZ305314B6 (cs) * 2010-12-30 2015-07-29 Zentiva, K.S. Nový hydrobromid formy C 5-[2-cyklopropyl-1-(2-fluorofenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráněným názvem prasugrel a způsob jeho výroby
CN102746318A (zh) * 2011-04-20 2012-10-24 上海信谊药厂有限公司 用于制备普拉格雷盐酸盐的方法
CN103102356B (zh) * 2011-11-11 2016-01-27 山东新时代药业有限公司 一种氢溴酸普拉格雷的制备方法
CZ2011872A3 (cs) * 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
CN103012427B (zh) * 2012-11-26 2015-07-08 天津大学 一种普拉格雷盐酸盐乙醇溶剂化物及其制备方法
CN103232446B (zh) * 2013-05-17 2015-09-23 天津药物研究院 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途
EP3106151A1 (fr) 2015-06-19 2016-12-21 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions pharmaceutiques de bromhydrate de prasugrel

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057593A2 (fr) * 2009-11-16 2011-05-19 Zentiva, K.S. Nouveaux sels de prasugrel et leur procédé de production

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE398624T1 (de) * 2000-07-06 2008-07-15 Daiichi Sankyo Co Ltd Säure-additionssalze von hydropyridinderivaten
TWI392681B (zh) * 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd 高純度普拉格雷及其酸加成鹽之製法
CN101255169B (zh) 2008-03-26 2010-11-10 山东大学 普拉格雷盐及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057593A2 (fr) * 2009-11-16 2011-05-19 Zentiva, K.S. Nouveaux sels de prasugrel et leur procédé de production

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011004392A1 *

Also Published As

Publication number Publication date
EP2451816A1 (fr) 2012-05-16
WO2011004392A1 (fr) 2011-01-13

Similar Documents

Publication Publication Date Title
EP2451816A4 (fr) Forme cristalline d'hydrobromure de prasugrel et son procédé de préparation
IL214822A0 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
SG10201605794PA (en) Stable Pharmaceutical Composition And Methods Of Using Same
EP2508170A4 (fr) Liposome d'irinotécan ou son hydrochlorure et son procédé d'obtention
AP3049A (en) New crystalline form VI of agomelatine, preparation method and application thereof
EP2364312A4 (fr) Synthèse de chlorhydrate de palonosétron cristallin
EP2470542A4 (fr) Préparation de la sitagliptine et de ses sels
PL3210991T3 (pl) Postać krystaliczna lewoizowalerylospiramycyny II oraz preparaty, sposoby wytwarzania i ich zastosowanie
EP2516404A4 (fr) Préparation de la bendamustine et de ses sels
ZA201107104B (en) Derivatives of benzothiazines,preparation thereof and application thereof as drugs
IL247929B (en) Stable compositions of 595–sns and methods for their preparation
EP2497766A4 (fr) Forme cristalline du bimatoprost, procédé de préparation et d'utilisation associé
EP2601200A4 (fr) Préparation de chlorhydrate de prasugrel
GB201210536D0 (en) Composition, use and method of preparation thereof
ZA201203531B (en) Certain crystalline hydrates, pharmaceutical compositions thereof and methods for preparation and use thereof
IL215512A0 (en) Substituted 1-alkylcinnolin-4(1h)-one derivatives, preparation thereof and therapeutic application of same
EP2626347A4 (fr) Polymorphe de dalfampridine, sa préparation et son application
PL2513099T3 (pl) Wytwarzanie związków n-monofluoroalkilowych
EP2459540A4 (fr) Préparation du fipamézole
GB201301307D0 (en) Crystalline form of prulifloxacin and processes for its preparation
GB201002278D0 (en) composition and method of preparation
HK1183888A (en) Preparation of crystalline ezatiostat hydrochloride ansolvate form d
HK1166785A (en) Salt of abt-263 and solid-state forms thereof
HK1170488A (en) Processes for the preparation of form i and form ii of palonosetron hydrochloride
RS20100352A3 (en) METHOD OF PREPARATION AND USE OF PHARMACOLOGICAL ACTIVE N-CARBAMYLMETHYL-4 (R) -Phenyl-2-Pyrrolidinone

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130128

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/10 20060101ALI20130122BHEP

Ipc: C07D 495/04 20060101AFI20130122BHEP

Ipc: A61P 7/02 20060101ALI20130122BHEP

Ipc: A61K 31/4365 20060101ALI20130122BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130827